In the past few decades, a considerable amount of interest has been generated in exploiting inter-organ signaling pathways, particularly organ-specific endocrine factors such as adipose-derived adiponectin, and liver-derived fibroblast growth factor 21, to treat metabolic disorders (223–225). This evidence concerns the gene ADIPOQ and Other metabolic disease.